GlassScriptPhysician profile
Amy Fay Jackson
NPI 1285235242
$1,086.38
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $347 · 2022: $194 · 2023: $189 · 2024: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $545.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organ Recovery Systems, INC. | $265.19 | 2024 | |
| Janssen Scientific Affairs, LLC | $231.37 | 2022-2023 | Xarelto |
| Janssen Pharmaceuticals, INC | $227.45 | 2021-2024 | Spravato |
| Esperion Therapeutics, INC. | $120.42 | 2021 | |
| Amgen INC. | $51.16 | 2021-2022 | |
| Baxter Healthcare | $45.89 | 2022-2023 | Preveleak |
| Astellas Pharma US INC | $34.15 | 2024 | Veozah |
| Smith+Nephew, INC. | $24.99 | 2023 | Renasys Go V2 Home |
| Kci USA, INC. | $21.26 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.42 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.15 | 2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $16.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.